...
首页> 外文期刊>Drug Design, Development and Therapy >Phoenixin 14 Inhibits High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Experimental Mice
【24h】

Phoenixin 14 Inhibits High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Experimental Mice

机译:Phoenixin 14在实验小鼠中抑制高脂饮食诱导的非酒精脂肪肝疾病

获取原文

摘要

Introduction: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases. The development of NAFLD is closely associated with hepatic lipotoxicity, inflammation, and oxidative stress. The new concept of NAFLD treatment is to seek molecular control of lipid metabolism and hepatic redox hemostasis. Phoenixin is a newly identified neuropeptide with pleiotropic effects. This study investigated the effects of phoenixin 14 against high-fat diet (HFD)-induced NAFLD in mice. Materials and Methods: For this study, we used HFD-induced NAFLD mice models to analyze the effect of phonenixin14. The mice were fed on HFD and normal diet and also given phoenixin 14 (100 ng/g body weight) by gastrogavage for 10 weeks. The peripheral blood samples were collected for biochemical assays. The liver tissues were examined for HFD-induced tissue fibrosis, lipid deposition and oxidative activity including SOD, GSH, and MDA. The liver tissues were analyzed for the inflammatory cytokines and oxidative stress pathway genes. Results: The results indicate that phoenixin 14 significantly ameliorated HFD-induced obesity and fatty liver. The biochemical analysis of blood samples revealed that phoenixin 14 ameliorated HFD-induced elevated circulating alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, and triglyceride levels, suggesting that phoenixin 14 has a protective role in liver function and lipid metabolism. Hematoxylin-eosin (HE) and Oil Red O staining of the liver showed that phoenixin 14 alleviated HFD-induced tissue damage and lipid deposition in the liver. Furthermore, the mice administered with phoenixin 14 had increased hepatic SOD activity, increased production of GSH and reduced MDA activity, as well as reduced production of TNF-α and IL-6 suggesting that phoenixin 14 exerts beneficial effects against inflammation and ROS. The findings suggest an explanation of how mechanistically phoenixin 14 ameliorated HFD-induced reduced activation of the SIRT1/AMPK and NRF2/HO-1 pathways. Conclusion: Collectively, this study revealed that phoenixin 14 exerts a protective effect in experimental NAFLD mice. Phoenixin could be of the interest in preventive modulation of NAFLD.
机译:简介:非酒精性脂肪肝病(NAFLD)是最常见的慢性肝病之一。 NAFLD的发展与肝脂毒性,炎症和氧化应激密切相关。 NAFLD治疗的新概念是寻求脂质代谢和肝脏氧化还原止血的分子控制。凤凰素是一种新鉴定的神经肽,具有脂肪效应。本研究研究了凤凰素14对小鼠高脂饮食(HFD)的影响 - 诱导小鼠的NAFLD。材料和方法:对于本研究,我们使用HFD诱导的NAFLD小鼠模型来分析Phonenixin14的效果。将小鼠送入HFD和正常饮食中,并通过胃肠饲禽给予腓醌14(100ng / g体重)10周。收集外周血样品以进行生物化学测定。检查肝组织的HFD诱导的组织纤维化,脂质沉积和氧化活性,包括SOD,GSH和MDA。分析肝组织的炎性细胞因子和氧化应激途径基因。结果:结果表明,凤凰素14显着改善了HFD诱导的肥胖和脂肪肝。血液样品的生化分析表明,凤凰素14改善了HFD诱导的循环丙氨酸氨基转移酶(ALT),天冬氨酸氨基转移酶(AST),总胆固醇和甘油三酯水平,表明腓醌14在肝功能和脂质代谢中具有保护作用。肝脏的血红素 - 曙红(He)和油红核染色肝脏表明,凤凰素14缓解了肝脏中的HFD诱导的组织损伤和脂质沉积。此外,用凤凰素14给药的小鼠具有增加的肝脏SOD活性,增加GSH的产生和减少的MDA活性,以及​​降低TNF-α和IL-6的产生,表明凤凰14对炎症和ROS产生有益的影响。研究结果表明了对机械凤凰14如何改善的HFD诱导的SIRT1 / AMPK和NRF2 / HO-1途径的解释。结论:集体,本研究表明,凤凰14在实验NAFLD小鼠中发挥了保护作用。凤凰宾可能对NAFLD的预防调制感兴趣。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号